Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review

Introduction: Mutation in Kristin ras sarcoma virus (KRAS) oncogene is the main driver in pancreatic ductal adenocarcinoma (PDAC) and is present in nearly 90% of patients with PDAC. Epidermal growth factor receptor (EGFR) mutation is rare in PDAC and is mostly present in the absence of KRAS mutation...

Full description

Bibliographic Details
Published in:	Case Reports in Oncology
Main Authors:	Juhi Mody, Mandana Kamgar
Format:	Article
Language:	English
Published:	Karger Publishers 2024-03-01
Subjects:	pancreatic duct cell carcinoma kras egfr case report erlotinib hydrochloride
Online Access:	https://beta.karger.com/Article/FullText/536552

Similar Items

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation
by: Alexander Siegman, et al.
Published: (2024-07-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
by: Demiray A, et al.
Published: (2018-12-01)

Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer
by: Yanli Guo, et al.
Published: (2024-12-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
by: Shen Shanxiang, et al.
Published: (2012-05-01)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
by: Didik Setyo Heriyanto, et al.
Published: (2022-12-01)

A case report of high-grade fetal lung adenocarcinoma with KRAS mutation
by: Wang Jiaqi, et al.
Published: (2024-01-01)

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma
by: Mahmoud Yousef, et al.
Published: (2025-04-01)

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
by: Masaoki Ito, et al.
Published: (2023-03-01)

Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
by: Szu-Aun Long, et al.
Published: (2024-05-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
by: Albert Grinshpun, et al.
Published: (2019-01-01)

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status
by: E.B. Faber, et al.
Published: (2024-06-01)

Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
by: Gaku Shimane, et al.
Published: (2024-09-01)

Codon-specific KRAS mutations predict survival in advanced pancreatic cancer
by: A. Boilève, et al.
Published: (2024-03-01)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
by: Prashanth Ashok Kumar, et al.
Published: (2023-06-01)

Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review
by: Yunpeng Wang, et al.
Published: (2022-10-01)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
by: Svenja Wagener-Ryczek, et al.
Published: (2020-05-01)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A case report supporting the concept of tumoral heterogeneity
by: Pegah Larki, et al.
Published: (2017-05-01)

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status
by: Oscar Arrieta, et al.
Published: (2020-04-01)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

A Case of Non-Small Cell Lung Cancer with Mutually Exclusive <i>EGFR</i> and <i>KRAS</i> Mutations
by: Abhimanyu Tushir, et al.
Published: (2025-01-01)

Analysis and characterization of chondroitin/dermatan sulfate composition of lung adenocarcinoma tissues with different types of genetic alterations in ALK, EGFR and KRAS oncogenes
by: Domonkos Pál, et al.
Published: (2025-06-01)

Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer
by: Nawaz Khan, et al.
Published: (2025-07-01)

Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients
by: He Cheng, et al.
Published: (2020-03-01)

Elevated KRAS protein level is associated with better survival in pancreatic cancer
by: S. M. Stålberg, et al.
Published: (2025-07-01)

Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors
by: Saeed Aslani, et al.
Published: (2025-10-01)

Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy
by: Kenneth K. Tanabe, et al.
Published: (2024-01-01)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
by: Natalie Carroll, et al.
Published: (2022-11-01)

Investigating the correlation between IDO1/PD-L1 expression or co-expression and EGFR/KRAS gene mutations in advanced NSCLC
by: Zhidong Yin, et al.
Published: (2025-08-01)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
by: Xiaoting Ma, et al.
Published: (2023-04-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer
by: Shuo Li, et al.
Published: (2021-07-01)

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
by: Anna Linehan, et al.
Published: (2024-03-01)

Autophagy induced during pancreatitis promotes KRAS-dependent transformation in the pancreas
by: Juan Iovanna
Published: (2016-10-01)

Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study
by: A. Gueiderikh, et al.
Published: (2024-02-01)

A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach
by: Syed Mohsin Raza, et al.
Published: (2023-06-01)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
by: Chen SC, et al.
Published: (2020-06-01)